Immatics NV (IMTX)
10.94
+0.13
(+1.20%)
USD |
NASDAQ |
May 17, 16:00
10.94
0.00 (0.00%)
After-Hours: 20:00
Immatics Revenue (Quarterly): 32.88M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 32.88M |
| December 31, 2023 | 17.15M |
| September 30, 2023 | 6.452M |
| June 30, 2023 | 24.38M |
| March 31, 2023 | 10.52M |
| December 31, 2022 | 38.50M |
| September 30, 2022 | 15.17M |
| June 30, 2022 | 18.34M |
| March 31, 2022 | 115.47M |
| December 31, 2021 | 17.99M |
| Date | Value |
|---|---|
| September 30, 2021 | 7.597M |
| June 30, 2021 | 6.254M |
| March 31, 2021 | 8.921M |
| December 31, 2020 | 11.26M |
| September 30, 2020 | 9.204M |
| June 30, 2020 | 7.595M |
| March 31, 2020 | 7.769M |
| December 31, 2019 | 4.854M |
| September 30, 2019 | 5.622M |
| June 30, 2019 | 6.048M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
4.854M
Minimum
Dec 2019
115.47M
Maximum
Mar 2022
18.60M
Average
9.863M
Median
Revenue (Quarterly) Benchmarks
| MorphoSys AG | 63.62M |
| Affimed NV | 0.4448M |
| InflaRx NV | 0.0391M |
| BioNTech SE | 203.77M |
| CureVac NV | 24.30M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -3.317M |
| Total Expenses (Quarterly) | 47.51M |
| EPS Diluted (Quarterly) | -0.0434 |
| Enterprise Value | 520.46M |
| Profit Margin (Quarterly) | -10.09% |
| Earnings Yield | -9.71% |
| Normalized Earnings Yield | -8.373 |